Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching to riociguat in patients with pulmonary arterial hypertension and an insufficient response to pho...

Full description

Bibliographic Details
Main Authors: Gérald Simonneau, Hossein-Ardeschir Ghofrani, Paul A. Corris, Stephan Rosenkranz, Ekkehard Grünig, Jim White, Vallerie V. McLaughlin, David Langleben, Christian Meier, Dennis Busse, Frank Kleinjung, Raymond L. Benza
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Pulmonary Circulation
Online Access:https://doi.org/10.1177/2045894020973124

Internet

https://doi.org/10.1177/2045894020973124

Similar Items